lonafarnib has been researched along with Co-infection in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilman, C; Heller, T; Koh, C | 1 |
| Deterding, K; Wedemeyer, H | 1 |
| Da, BL; Glenn, JS; Koh, C | 1 |
3 review(s) available for lonafarnib and Co-infection
| Article | Year |
|---|---|
Chronic hepatitis delta: A state-of-the-art review and new therapies.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Global Burden of Disease; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Organic Anion Transporters, Sodium-Dependent; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Review Literature as Topic; Superinfection; Symporters; Therapies, Investigational; Treatment Outcome; Virus Assembly; Virus Internalization | 2019 |
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Drug-Related Side Effects and Adverse Reactions; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Polymers; Pyridines; Recurrence; Treatment Outcome | 2019 |
HBV/HDV Coinfection: A Challenge for Therapeutics.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drugs, Investigational; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Piperidines; Polyethylene Glycols; Prognosis; Pyridines; Recombinant Proteins; Risk Assessment; Treatment Outcome | 2019 |